Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy

Condition:   Type 2 Diabetes
Interventions:   Other: 24-hour intervention with multiple daily injections;   Other: 24-hour intervention with closed-loop strategy;   Drug: Insulin;   Device: Insulin pump MiniMed® Paradigm® Veo™;   Device: Continuous Glucose Monitoring System Enlite sensor®
Sponsors:   Institut de Recherches Cliniques de Montreal;   Réseau de recherche en santé cardiométabolique, diabète et obésité
Not yet recruiting - verified July 2015

Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: Laparoscopic Sleeve Gastrectomy plus conventional medical therapy;   Drug: Conventional medical therapy
Sponsors:   Azienda Ospedaliera Santa Maria, Terni, Italy;   Ethicon Endo-Surgery
Not yet recruiting - verified June 2015

Multi-centre Peer Support Program in Type 2 Diabetes Patients in Hong Kong

Conditions:   Type 2 Diabetes;   Peer Group
Intervention:   Behavioral: Peer support program
Sponsor:   Chinese University of Hong Kong
Not yet recruiting - verified June 2015

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Conditions:   Pain;   Chronic Pain;   Mental Disorders;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2;   Arthritis
Interventions:   Other: Unblinded to Genetic Testing Results;   Other: Blinded to Genetic Testing Results
Sponsor:   Proove Bioscience, Inc.
Recruiting - verified June 2015

Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea

Condition:   Type 2 Diabetes
Intervention:   Other: Observational
Sponsor:   Institut de Recherches Cliniques de Montreal
Not yet recruiting - verified June 2015

Family-Focused Mobile Health Intervention

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Family-focused components (FFC);   Behavioral: Individual text messaging
Sponsor:   Vanderbilt University
Not yet recruiting - verified June 2015

Efficacy and Safety of Lobeglitazone Versus Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lobelitazone 0.5mg;   Drug: Sitagliptin 100mg
Sponsor:   Chong Kun Dang Pharmaceutical
Recruiting - verified May 2015

Complications in Central American Diabetic Patients: Historic Cohort

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: None, observational study
Sponsors:   Clínica Los Yoses;   Novo Nordisk A/S
Not yet recruiting - verified June 2015

DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)

Condition:   Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Glimepiride;   Drug: Metformin
Sponsors:   Diabetes Frail Ltd;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified June 2015

Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Virtual Diabetes Self-Care and Education Program;   Device: Fitbit;   Device: Smartphone
Sponsors:   Joslin Diabetes Center;   Verizon Foundation;   Doctors Hospital at Renaissance
Recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Not yet recruiting - verified June 2015

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2015

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Effects of Polyphenols Found in Pomegranate and Bonolive on Postprandial Blood Glucose in Vivo.

Condition:   Hyperglycaemia
Interventions:   Other: Control (109 g white bread);   Dietary Supplement: Dose 1 (pomegranate or bonolive);   Dietary Supplement: Dose 2 (pomegranate or bonolive)
Sponsor:   University of Leeds
Recruiting - verified June 2015

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

The Combined Portfolio Diet and Exercise Study

Conditions:   Cardiovascular Diseases;   Hypercholesterolemia;   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Behavioral: Portfolio Plus Diet;   Behavioral: DASH-like (high fiber) Diet
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research  (CIHR);   University of Toronto;   Laval University;   University of Manitoba;   University of British Columbia
Not yet recruiting - verified June 2015

Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus

Condition:   Diabetes Mellitus Gestational Previous Pregnancy
Intervention:   Behavioral: Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus
Sponsor:   Athabasca University
Not yet recruiting - verified June 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified June 2015

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Recruiting - verified July 2015

The Effect of Dairy and Non-dairy Snacks on Food Intake, Subjective Appetite in Children

Conditions:   Energy Intake;   Appetite
Intervention:   Other: Dietary treatment
Sponsors:   Mount Saint Vincent University;   University of Toronto
Completed - verified June 2015

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2015

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Condition:   Type II Diabetes
Interventions:   Drug: Farxiga;   Drug: Placebo;   Drug: Metformin;   Drug: Insulin
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea

Conditions:   Diabetes;   Obstructive Sleep Apnea
Interventions:   Device: CPAP;   Other: Control
Sponsors:   Nordsjaellands Hospital;   Aarhus University Hospital
Recruiting - verified June 2015

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300) HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Conditions:   Diabetes;   PTH;   Vitamin D;   Fibroblast Growth Factor (FGF23);   Phosphate
Interventions:   Drug: Placebo;   Drug: Canagliflozin
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2015

Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Nutritional Counseling;   Other: Usual Diet Guidance
Sponsor:   Hospital de Clinicas de Porto Alegre
Recruiting - verified June 2015

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

Effects of Physical Exercise on Blood Glucose and Pain From the Muskuloskeletal System in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Exercise training
Sponsor:   Nordsjaellands Hospital
Recruiting - verified February 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified June 2015

E-coaching for Type 2 Diabetes

Conditions:   Abdominal Obesity;   Type 2 Diabetes
Intervention:   Behavioral: e-coaching
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified July 2015

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: GEMIGLIPTIN LS15-0444;   Drug: vildagliptin;   Drug: metformin
Sponsor:   Sanofi
Recruiting - verified July 2015

Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Abbott Sensor Based Glucose Monitoring System-Professional
Sponsor:   Abbott Diabetes Care
Recruiting - verified June 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Glibenclamide
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2015

Hartmann's Solution and Normal Saline in Type II Diabetes Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Hartmann's solution;   Drug: Normal saline
Sponsor:   Yeungnam University College of Medicine
Recruiting - verified June 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Condition:   Diabetes
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified October 2014

Canola-Mediterranean Diet Study in T2DM

Conditions:   Type 2 Diabetes;   Obesity;   Overweight;   Cardiovascular Diseases
Interventions:   Behavioral: A canola oil enriched mediterranean diet;   Behavioral: A high wheat fiber diet
Sponsors:   St. Michael's Hospital, Toronto;   University of Toronto;   Laval University;   University of Manitoba;   Canola Council of Canada
Recruiting - verified June 2015

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Recruiting - verified June 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Recruiting - verified June 2015

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Condition:   Type 2 Diabetes
Interventions:   Drug: Mylan's insulin glargine;   Drug: Lantus®
Sponsors:   Mylan Inc.;   Mylan GmbH
Active, not recruiting - verified June 2015

The Effects of Apple Consumption on Cardiovascular Health in Prediabetics andType 2 Diabetics

Conditions:   Diabetes;   Cardiovascular Diseases;   Prediabetes
Interventions:   Dietary Supplement: Apple;   Dietary Supplement: Placebo
Sponsors:   Florida State University;   U.S. Apple Association
Recruiting - verified June 2015

Deep Brain Stimulation for Human Morbid Obesity

Condition:   Obesity
Intervention:   Device: Deep Brain Stimulation
Sponsor:   Hospital do Coracao
Active, not recruiting - verified June 2015

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified July 2015

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Condition:   Gastroparesis
Interventions:   Drug: Placebo;   Drug: Camicinal
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2015

Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Home telehealth system
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified June 2015

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine;   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Completed - verified June 2015

Hypoxia and Exercise in the Elderly

Condition:   Elderly Persons
Interventions:   Other: Hypoxic exercise;   Other: Normoxic Exercise
Sponsors:   Hannover Medical School;   German Diabetes Center
Recruiting - verified June 2015

Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Hyperglycemia
Intervention:   Drug: ex vivo Activated Immune Cells
Sponsors:   B & Y Technologies;   The 12th People's Hospital of Guangzhou City;   The 12th People's Hospital of Shenzhen City
Recruiting - verified June 2015

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Condition:   Healthy Volunteer, Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: RO6799477
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   NIDDM;   Non-insulin Dependent Diabetes Mellitus
Intervention:   Behavioral: Home Visits and Lifestyle Education Support
Sponsors:   McMaster University;   Ontario Ministry of Health and Long Term Care;   Canadian Institutes of Health Research  (CIHR)
Active, not recruiting - verified June 2015

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Condition:   Diabetes Mellitus Type 2
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified March 2014

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: BI 187004;   Drug: Placebo;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified June 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified June 2015

RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:  
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   University of Oxford;   Oxford University Hospitals NHS Trust;   University of Dundee;   NHS Tayside
Active, not recruiting - verified June 2015

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:   Drug: second- or third-line glucose-lowering diabetes treatment
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   King's College London;   King's College Hospital NHS Trust;   University of Glasgow;   NHS Greater Glasgow and Clyde;   Newcastle University;   Newcastle-upon-Tyne Hospitals NHS Trust;   Oxford University Hospitals NHS Trust
Active, not recruiting - verified June 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified June 2015

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Miami
Recruiting - verified June 2015

Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men

Condition:   Alzheimer's Disease
Intervention:  
Sponsors:   University of Eastern Finland;   King's College London;   Sahlgrenska University Hospital, Sweden;   Janssen Pharmaceutica
Enrolling by invitation - verified June 2015

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LAF237 50 mg;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed - verified July 2015

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified June 2015

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified June 2015

Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.

Conditions:   Obesity;   Type 2 Diabetes;   Bariatric Surgery
Interventions:   Procedure: Roux-en-Y gastric bypass;   Procedure: sleeve gastrectomy
Sponsor:   Göteborg University
Recruiting - verified June 2015

Diet and Exercise Intervention in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Optimum Lifestyle Intervention;   Behavioral: Standard Care
Sponsors:   Washington University School of Medicine;   National Dairy Council;   American Egg Board
Recruiting - verified June 2015

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified July 2015

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Active, not recruiting - verified June 2015

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified July 2015

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended - verified August 2014

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified June 2015

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Vitamin D;   Drug: Placebo
Sponsor:   University of Florida
Completed - verified June 2015

The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control

Condition:   Glycemic Control for Diabetes Mellitus
Interventions:   Behavioral: Empowerment model to improve dietary intake;   Other: Control group following conventional approach
Sponsor:   SEAMEO Regional Centre for Food and Nutrition
Completed - verified June 2015

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2015

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3012;   Drug: Metformin;   Drug: Placebo to metformin;   Drug: Glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus

Condition:   Gestational Diabetes Mellitus
Intervention:   Other: blood sample
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified July 2015

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2015

Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region

Condition:   Diabetes
Interventions:   Other: JADE;   Other: DIAMOND
Sponsor:   Asia Diabetes Foundation
Active, not recruiting - verified June 2015

Fibrosis a New Pathological Actor in Adipose Tissue

Conditions:   Obesity;   Metabolic Diseases;   Fibrosis;   Body Weight
Intervention:   Procedure: biopsy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified April 2015

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2015

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2015

Mechanisms of Diabetes Relapse After Bariatric Surgery

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   Columbia University
Not yet recruiting - verified July 2015

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified July 2015

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

Condition:   Intrahepatic Cholestasis of Pregnancy (ICP), Gestational Diabetes Mellitus (GDM)
Intervention:  
Sponsor:   Imperial College London
Recruiting - verified March 2015

Mifepristone for Metabolic Syndrome

Conditions:   Endocrine Disease;   Diabetes
Intervention:   Drug: Mifepristone
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2015

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Biospecimens for Identification of Diseases of the Pancreas.

Conditions:   Pancreatic Cancer;   Chronic Pancreatitis;   Type II Diabetes;   Pancreatic Cysts;   Healthy Control
Intervention:   Procedure: Blood Draw
Sponsor:   University of Michigan
Recruiting - verified June 2015

Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: placebo
Sponsors:   University of Alabama at Birmingham;   Amylin Pharmaceuticals, LLC.
Recruiting - verified May 2015

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultants

Condition:   Diabetes
Intervention:   Other: Structured care led by a nurse consultant
Sponsor:   Asia Diabetes Foundation
Completed - verified May 2011

Effect of Lycopene and Isoflavones on Glucose Metabolism

Conditions:   Metabolic Syndrome;   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks;   Other: Screening;   Other: OGTT;   Other: Anthropometrics and Blood pressure;   Other: Screening;   Other: Blood Drawing
Sponsor:   The University of Texas Medical Branch, Galveston
Withdrawn - verified June 2015

Insulin Detemir in Obesity Management

Conditions:   Diabetes;   Obesity
Intervention:   Drug: Detemir
Sponsors:   Vanderbilt University;   Novo Nordisk A/S
Active, not recruiting - verified June 2015

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified June 2015

Psoriasis Inflammation and Systemic Co Morbidities

Condition:   Psoriasis
Intervention:  
Sponsors:   Rockefeller University;   Weill Medical College of Cornell University
Active, not recruiting - verified June 2015

Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified July 2015

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: insulin glargine;   Drug: insulin glulisine
Sponsor:   Novo Nordisk A/S
Completed - verified June 2015

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Sitagliptin Cardiovascular Outcome Study (MK-0431-082)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Completed - verified June 2015

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Condition:   Cardiovascular Diseases
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: simvastatin;   Drug: pravastatin
Sponsors:   Hospital Universitario 12 de Octubre;   Merck Sharp & Dohme Corp.
Completed - verified August 2008

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia

Condition:   Type 2 Diabetes
Interventions:   Procedure: Double-balloon enteroscopy;   Other: Standard meal test
Sponsor:   University Hospital, Gentofte, Copenhagen
Completed - verified June 2015

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: Pramlintide acetate
Sponsor:   AstraZeneca
Completed - verified June 2015

Get CardioSmart

You're Invited